Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9539250 | MELINTA | Salt and crystalline forms thereof of a drug |
Oct, 2025
(2 years from now) | |
US8273892 | MELINTA | Salt and crystalline forms thereof of a drug |
Aug, 2026
(2 years from now) | |
US8871938 | MELINTA | Process for making quinolone compounds |
Sep, 2029
(5 years from now) | |
USRE46617 | MELINTA | Process for making quinolone compounds |
Dec, 2029
(6 years from now) | |
US7728143 | MELINTA | Salt and crystalline forms thereof of a drug |
Jun, 2031
(7 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8969569 | MELINTA | Salt and crystalline forms thereof of a drug |
Oct, 2025
(2 years from now) | |
US8648093 | MELINTA | Salt and crystalline forms thereof of a drug |
Oct, 2025
(2 years from now) | |
US8252813 | MELINTA | Salt and crystalline forms thereof of a drug |
Oct, 2026
(3 years from now) | |
US7635773 | MELINTA | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(5 years from now) | |
US9200088 | MELINTA | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(5 years from now) | |
US8410077 | MELINTA | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(5 years from now) | |
US9750822 | MELINTA | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(5 years from now) | |
US9493582 | MELINTA | Alkylated cyclodextrin compositions and processes for preparing and using the same |
Feb, 2033
(9 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jun 19, 2022 |
Generating Antibiotic Incentives Now (GAIN) | Jun 19, 2027 |
Drugs and Companies using DELAFLOXACIN MEGLUMINE ingredient
NCE-1 date: 2026-06-19
Market Authorisation Date: 19 June, 2017
Treatment: Treatment of acute bacterial skin and skin structure infections caused by designated susceptible bacteria in adults
Dosage: POWDER;INTRAVENOUS
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic